R01CA266803

AN IONIZING RADIATION ACOUSTICS IMAGING (IRAI) APPROACH FOR GUIDED FLASH RADIOTHERAPY - SUMMARY

AN EMERGING RADIOTHERAPY (RT) MODALITY THAT UTILIZES ULTRA-HIGH DOSE RATE, KNOWN AS FLASH-RT, HAS DEMONSTRATED UNPRECEDENTED ABILITY FOR IMPROVING RT THERAPEUTIC RATIO IN PRECLINICAL STUDIES AND EARLY CLINICAL CASES.

BECAUSE OF LACK OF APPROPRIATE IMAGE-GUIDANCE TECHNOLOGIES, THESE STUDIES HAVE BEEN LIMITED TO SUPERFICIAL IRRADIATIONS AND SIMPLISTIC CASES WHERE MONITORING OF DELIVERED DOSE IS PERMISSIBLE USING EXISTING METHODS. THIS SEVERELY HANDICAPS THE PROSPECTS OF FLASH-RT AND LARGELY LIMITS ITS PROMISING IMPACT FOR DEEP SEATED TUMORS, WHICH CONSTITUTE MOST OF RT CANCER CASES.

IT IS WIDELY RECOGNIZED THAT CURRENTLY USED DOSIMETRY TECHNOLOGIES FALL SHORT OF PROVIDING THE NECESSARY GUIDANCE TO DELIVER FLASH-RT IN A PRACTICAL CLINICAL SETTING WITHOUT EXPOSING THE PATIENT TO TREMENDOUS RISKS THAT GO FAR BEYOND THE TRADITIONAL RT DELIVERY.

UNDOUBTEDLY, THERE IS AN UNMET NEED TO DEVELOP IN VIVO IMAGE-GUIDANCE TECHNIQUES TO SAFEGUARD FLASH-RT ACCURATE DELIVERY. WE HOLD THAT THESE CHALLENGES CAN BE RESOLVED BY REFINING THE EMERGING TECHNOLOGY OF IONIZING RADIATION-INDUCED ACOUSTIC IMAGING (IRAI), WHICH CAN BE INTRINSICALLY PAIRED WITH FLASH-RT DELIVERY SYSTEMS.

IRAI IS BASED ON THE KNOWN THERMOACOUSTIC PHENOMENON IN RADIATION PHYSICS, WHERE ACOUSTIC WAVES ARE GENERATED FROM THERMOELASTIC EXPANSION OF A SUBSTANCE FOLLOWING ABSORPTION OF PENETRATING PULSATED HIGH ENERGY RADIATION.

BUILDING UPON OUR MULTI-INSTITUTIONAL MULTIDISCIPLINARY TEAM WITH EXPERTISE IN ULTRASOUND (US) IMAGING, RT PHYSICS, DATA ANALYTICS, AND OUR PROMISING PRELIMINARY RESULTS, WE HYPOTHESIZE THAT: (1) A DUAL-MODALITY IMAGING SYSTEM COMPRISED OF IRAI AND US (IRAI-US) CAN SIMULTANEOUSLY IMAGE BOTH TISSUE MORPHOLOGY AND 3D DOSE DEPOSITION DURING FLASH-RT DELIVERY WITH HIGH SPATIO-TEMPORAL RESOLUTIONS; AND (2) MACHINE LEARNING BASED RECONSTRUCTION AND ANOMALY DETECTION CAN EFFECTIVELY IMPROVE IMAGING QUALITY AND MITIGATE ERRORS, RESPECTIVELY, FOR CLINICAL TRANSLATION.

THEREFORE, IN THIS PROJECT WE AIM TO EXPLOIT THE TECHNOLOGICAL POTENTIALS OF IRAI-US AND MACHINE LEARNING FOR DEVELOPING AN IMAGE-GUIDANCE PLATFORM FOR EFFECTIVE AND SAFE FLASH-RT DELIVERY. WE WILL DEMONSTRATE ITS EFFICACY WITH ELECTRON AND PROTON BEAMS USING COMPUTER SIMULATIONS (IN SILICO), TISSUE MIMICKING PHANTOMS, AND RELEVANT PRECLINICAL IN VIVO MODELS.

SPECIFICALLY, WE WILL (1) DEVELOP AND TEST A DUAL-MODE IMAGING SYSTEM FOR 3D RADIATION-ACOUSTICS DOSIMETRY AND US IMAGING FOR FLASH-RT; (2) EVALUATE THE IN VIVO PERFORMANCE OF IRAI-US DUAL IMAGING DURING ELECTRON AND PROTON FLASH-RT DELIVERIES; AND (3) ADAPT AND IMPROVE IRAI VOLUMETRIC REPRESENTATION, TEMPORAL RESOLUTION AND ERROR DETECTION FOR FLASH-RT USING DEEP MACHINE LEARNING ALGORITHMS (DEEPRAI) TOWARDS EFFECTIVE CLINICAL IMPLEMENTATION.

IMPACT: OUR PROPOSED IMAGE-GUIDED FLASH-RT, ONCE VALIDATED, WILL OFFER A PRACTICAL, ROBUST, COST-EFFECTIVE, AND UNIQUE SYSTEM FOR SAFEGUARDING FLASH-RT DELIVERY. THESE ADVANCEMENTS WILL ADDRESS THE CURRENT CHALLENGES IMPEDING THE CLINICAL TRANSLATION OF FLASH-RT AND ENABLE ACHIEVING ITS PROMISE OF LIMITING RADIOTHERAPY TOXICITY TO NORMAL TISSUES AND THEREBY IMPROVING CANCER PATIENT CARE AND QUALITY OF LIFE.

H. Lee Moffitt Cancer Center And Research Institute Hospital

TO DEVELOP THE MEANS TO CURE AS MANY CANCER PATIENTS AS POSSIBLE AND TO CONTROL THE DISEASE IN THOSE PATIENTS WHO ARE NOT CURED. CANCER TREATMENT RESEARCH INCLUDES THE DEVELOPMENT AND EVALUATION OF IMPROVED METHODS OF CANCER TREATMENT THROUGH THE SUPPORT AND PERFORMANCE OF BOTH FUNDAMENTAL AND APPLIED LABORATORY AND CLINICAL RESEARCH. RESEARCH IS SUPPORTED IN THE DISCOVERY, DEVELOPMENT, AND CLINICAL TESTING OF ALL MODES OF THERAPY INCLUDING: SURGERY, RADIOTHERAPY, CHEMOTHERAPY, AND BIOLOGICAL THERAPY INCLUDING MOLECULARLY TARGETED THERAPIES, BOTH INDIVIDUALLY AND IN COMBINATION. IN ADDITION, RESEARCH IS CARRIED OUT IN AREAS OF NUTRITIONAL SUPPORT, STEM CELL AND BONE MARROW TRANSPLANTATION, IMAGE GUIDED THERAPIES AND STUDIES TO REDUCE TOXICITY OF CYTOTOXIC THERAPIES, AND OTHER METHODS OF SUPPORTIVE CARE THAT MAY SUPPLEMENT AND ENHANCE PRIMARY TREATMENT. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.395 - Cancer Treatment Research

National Cancer Institute (NCI) [HHS - NIH]

Tampa, Florida 336129497 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 426% from $619,897 to $3,262,628.